Skip to main content
. Author manuscript; available in PMC: 2017 Aug 8.
Published in final edited form as: Gene Ther. 2014 Nov 27;22(2):209–215. doi: 10.1038/gt.2014.104

Figure 2.

Figure 2

CD19-CAR expression and ex vivo expansion of Tol2-modified T-cells. (a) Surface expression of CD19-CAR on T-cells after nucleofection with pTol2-CD19-CAR with or without pCAGGS-mT2TP (TPase) plasmids was examined by flow cytometry. Values represent the percentages of CD3+ CD19-CAR+ and CD3− CD19-CAR+ cells. Data are representative of one of the three independent experiments using different donors. (b) CD19-CAR expression of Tol2-tranduced T-cells in the presence or absence of TPase as detected by western blotting with an anti-CD3ζ antibody. β-Actin was used as a loading control. (c) Growth rates of transduced T-cells with or without TPase. 3T3/CD19 cells were added weekly. Viable cells were enumerated by trypan blue exclusion. Data represent mean ± s.d. from three different donors.